Common Technical Challenges with Outsourcing Nonclinical Studies

Presented by

Scott Boley, PhD, DABT, Greg Ruppert, BA

About this talk

A primary challenge for pharmaceutical and biotechnology companies in developing their drugs is to carefully assess the relationship between efficacy and toxicity before entering into human clinical trials. Nonclinical testing is required to evaluate the potential efficacy of a new therapeutic and establish a safe starting dose for initial human clinical trials. Knowing when and where to invest your time and effort in preparing for these nonclinical studies is a critical component of a company’s drug development strategy. Many companies outsource their nonclinical testing to contract research organizations (CROs) and have little to no prior experience in working with a CRO. There are a number of technical challenges involved in the process of outsourcing, which if not taken under consideration, can cause delays and unexpected expenses in developing a compound. These challenges range from determining which species is appropriate for your project to basic formulation and dosing aspects. Being aware of and mitigating as many of these challenges early in the process as possible reduces the potential for delays and allows a company to proceed with increased confidence. This webinar will describe some common technical challenges that we have encountered while working with our Sponsors.

Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (9)
Subscribers (2035)
MPI Research exceeds expectations through consistency and quality, with a commitment to communication and innovation, delivering benefits throughout all phases of drug and device development. Learn how we can go beyond for you at